Data presented at Psych Congress 2024 showed improvements in social functioning and quality of life over an eight-week ...

Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk ...

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a ...

Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the ...

044). Conversely, 6 taxa, such as rhodospirillaceae, defluviitaleaceae, and desulfovibrio, were protective against schizophrenia (OR: 0.88-0.94; P ≤.049). The findings may provide evidence for the ...

For the past 70 years, schizophrenia treatments all targeted the same chemical: dopamine. While that works for some, it ...

Schizophrenia significantly shortens life expectancy by an estimated 15 years with excess mortality arising from multiple ...

Art therapy can help individuals express thoughts and feelings without relying solely on words, providing a valuable outlet ...

There are a few unmet needs in schizophrenia that can make a big difference in the prognosis and quality of life of patients.

Leal Therapeutics has secured yet another multi-million financing deal as the Worcester-based biotechnology startup has ...

This study explored the agreement or discrepancy between subjective difficulties in social cognition and actual cognitive ...